Q4 2025 · 13F-HR
Rosalind Advisors, Inc.holdings as filed
Filed 2026-02-12 · accession 0001622627-26-000011
$284.5M
Reported value
42
Positions
2025-12-31
Period end
The Brief · Rosalind Advisors, Inc. · Q4 2025
AI · grounded in 13F
Rosalind Advisors, Inc. exited its position in RZLT, reducing its exposure by $16.99M. The fund established a new position in REPL worth $13.71M and added AVBP with a $4.34M investment. Additionally, the fund increased its holdings in XFOR and PROF by 68.71% and 54.43% respectively.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 24661P807 | DCTH | DELCATH SYSTEMS, INC. | $33.0M | 11.6% | 3,300,389 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $20.5M | 7.21% | 3,403,721 | Common | SOLE |
| 31447P100 | FENC | FENNEC PHARMACEUTICALS INC | $20.1M | 7.07% | 2,613,508 | Common | SOLE |
| 98422E103 | XERS | XERIS BIOPHARMA HOLDGS INC | $16.6M | 5.83% | 2,111,700 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $14.0M | 4.92% | 450,000 | Common | SOLE |
| M68830112 | MDWD | MEDIWOUND LTD | $13.8M | 4.86% | 749,054 | Common | SOLE |
| 92337C203 | VSTM | VERASTEM INC | $13.8M | 4.85% | 1,788,475 | Common | SOLE |
| 76029N106 | REPL | REPLIMUNE GROUP INC | $13.7M | 4.82% | 1,410,497 | Common | SOLE |
| 002120202 | ATYR | ASTRIA THERAPEUTICS INC | $13.6M | 4.78% | 1,039,080 | Common | SOLE |
| 23256X407 | HELP | CYBIN INC | $13.6M | 4.77% | 1,657,540 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $12.6M | 4.43% | 690,000 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $12.5M | 4.38% | 300,000 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $12.4M | 4.36% | 195,045 | Common | SOLE |
| 98420X202 | XFOR | X4 PHARMACEUTICALS INC | $10.4M | 3.66% | 2,605,920 | Common | SOLE |
| 60255C885 | BRD1EUR | MIND MEDICINE MINDMED INC | $10.0M | 3.53% | 750,000 | Common | SOLE |
| 74319B502 | PROF | PROFOUND MEDICAL CORP | $8.4M | 2.96% | 1,068,955 | Common | SOLE |
| 45779A846 | NSPR | INSPIREMD INC | $7.0M | 2.44% | 3,905,743 | Common | SOLE |
| 67576A100 | OCUL | Ocular Therapeutix, Inc | $4.9M | 1.71% | 400,000 | Common | SOLE |
| 04272N102 | AVBP | ARRIVENT BIOPHARMA INC | $4.3M | 1.53% | 215,871 | Common | SOLE |
| 00444T209 | TLPH | TALPHERA INC | $4.1M | 1.43% | 3,579,273 | Common | SOLE |
| 62857J201 | MYO | MYOMO INC | $3.5M | 1.23% | 3,839,772 | Common | SOLE |
| 46090E953 | QQQ | INVESCO QQQ TR | $3.0M | 1.06% | 450,000 | PUT | SOLE |
| M8001Q126 | PYPD | POLYPID LTD | $3.0M | 1.06% | 696,556 | Common | SOLE |
| 68277Q105 | OKUR | ONKURE THERAPEUTICS INC | $2.1M | 0.74% | 730,488 | Common | SOLE |
| 78462F953 | SPY | SPDR S&P 500 ETF TR | $1.9M | 0.66% | 510,000 | PUT | SOLE |
| 032797950 | AVXL | ANAVEX LIFE SCIENCES CORP | $1.9M | 0.66% | 1,168,600 | PUT | SOLE |
| M8211G108 | RGNT | REGENTIS BIOMATERIALS LTD | $1.7M | 0.60% | 251,510 | Common | SOLE |
| 78464A950 | — | SPDR SERIES TRUST | $1.3M | 0.47% | 1,937,600 | PUT | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $1.3M | 0.44% | 100,000 | Common | SOLE |
| 464287955 | — | ISHARES TR | $1.1M | 0.39% | 200,000 | PUT | SOLE |
| 64134X201 | NRXS | NEURAXIS INC | $1.0M | 0.37% | 286,138 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $1.0M | 0.37% | 100,000 | Common | SOLE |
| 35168W103 | GUTS | FRACTYL HEALTH INC | $848,608 | 0.30% | 385,731 | Common | SOLE |
| 09077D209 | BFRI | BIOFRONTERA INC | $650,235 | 0.23% | 1,140,764 | Common | SOLE |
| 04272N902 | AVBP | ARRIVENT BIOPHARMA INC | $539,500 | 0.19% | 107,900 | CALL | SOLE |
| 92337C903 | VSTM | VERASTEM INC | $159,810 | 0.06% | 268,600 | CALL | SOLE |
| N90064901 | QURE | UNIQURE NV | $95,000 | 0.03% | 100,000 | CALL | SOLE |
| 76029N906 | REPL | REPLIMUNE GROUP INC | $11,545 | 0.00% | 230,900 | CALL | SOLE |
| 92686J906 | VKTX | VIKING THERAPEUTICS INC | $2,000 | 0.00% | 100,000 | CALL | SOLE |
| 76029N956 | REPL | REPLIMUNE GROUP INC | $0 | — | 264,700 | PUT | SOLE |
| 92840H900 | VTGN | VISTAGEN THERAPEUTICS INC | $0 | — | 493,400 | CALL | SOLE |
| 76200L909 | RZLT | REZOLUTE INC | $0 | — | 263,100 | CALL | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.